Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of S086 plus amlodipine in primary hypertension uncontrolled on S086 monotherapy
CTR20244587Phase 3Completed
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Dec 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of S086 in essential hypertension, sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. Started Dec 2024; status: completed.
02
Drugs
S086
03
Conditions
essential hypertension
Beyond the preview
Go deeper on CTR20244587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244587.